Lecanemab

Eisai: "LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in China

Retrieved on: 
Wednesday, January 10, 2024
BIIB, Patient, MCI, Insurance, Alzheimer's disease, Lecanemab, Biogen, Biomarker, Marketing, Brain, Ageing, Clarity

Preparations for launch within the second quarter of Eisai's FY 2024 (July 1 - September 30, 2024) are underway.

Key Points: 
  • Preparations for launch within the second quarter of Eisai's FY 2024 (July 1 - September 30, 2024) are underway.
  • LEQEMBI is the first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline through this mechanism.
  • China is the third country to grant marketing approval, following the traditional approval in the U.S. in July 2023 and Japanese approval in September 2023.
  • ** An online business of Jingyi Weixiang (Shanghai) Health Industry Development Limited Company, a joint venture company with JD Health.

Leqembi® approved for the treatment of Alzheimer's disease in China

Retrieved on: 
Tuesday, January 9, 2024
Patient, MCI, Insurance, Memory, Eisai, Lecanemab, Biomarker, Marketing, Brain, Ageing, Clarity, Pharmaceutical industry

China is the third country to grant marketing approval, following the traditional approval in the United States in July 2023 and Japanese approval in September 2023.

Key Points: 
  • China is the third country to grant marketing approval, following the traditional approval in the United States in July 2023 and Japanese approval in September 2023.
  • Leqembi is the first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline through this mechanism.
  • Eisai will distribute the product in China and will conduct information provision activities through specialized Medical Representatives.
  • Dosage and administration: The usual dose of lecanemab (recombinant) is 10mg/kg infused intravenously over approximately 1 hour, once every 2 weeks.

Leqembi® approved for the treatment of Alzheimer's disease in China

Retrieved on: 
Tuesday, January 9, 2024
Patient, MCI, Insurance, Memory, Eisai, Lecanemab, Biomarker, Marketing, Brain, Ageing, Clarity, Pharmaceutical industry

China is the third country to grant marketing approval, following the traditional approval in the United States in July 2023 and Japanese approval in September 2023.

Key Points: 
  • China is the third country to grant marketing approval, following the traditional approval in the United States in July 2023 and Japanese approval in September 2023.
  • Leqembi is the first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline through this mechanism.
  • Eisai will distribute the product in China and will conduct information provision activities through specialized Medical Representatives.
  • Dosage and administration: The usual dose of lecanemab (recombinant) is 10mg/kg infused intravenously over approximately 1 hour, once every 2 weeks.

LEQEMBI Wins Best New Drug And Clinical Advance of The Year at The Scrip Awards 2023

Retrieved on: 
Monday, November 20, 2023
Phase, Alzheimer's disease, Dementia, Biogen, BIIB, Disease, Clinical trial, Lecanemab, Scrip, Pathology, Eisai, Pharmaceutical industry

The Scrip Awards, now in its 19th year, celebrates the best innovations and achievements of the international biopharma industry.

Key Points: 
  • The Scrip Awards, now in its 19th year, celebrates the best innovations and achievements of the international biopharma industry.
  • The award for Clinical Advance of the Year recognizes the success of a new drug product in a clinical trial that is expected to lead to an advance in healthcare.
  • It was awarded for the success of the Phase III Clarity AD study of LEQEMBI.
  • Eisai and Biogen deeply appreciate the cooperation of people living with AD and healthcare professionals who participated in LEQEMBI's clinical studies.

AdaptIV Infusion Now Offering Leqembi® Infusion Therapy for Alzheimer's Patients at Sugar Land Clinic

Retrieved on: 
Thursday, December 21, 2023
Patient, Alzheimer's disease, MRI, FDA, Health, Ageing, Lecanemab, Myenteric plexus, Snack, Insurance, Memory, Eisai, CMS, Medical device

SUGAR LAND, Texas, Dec. 21, 2023 /PRNewswire-PRWeb/ -- AdaptIV Infusion, a state-of-the-art ambulatory infusion clinic specializing in autoimmune disorders, complex chronic conditions, and health and wellness therapies, is now one of a select few facilities administering Leqembi® (lecanemab-irmb) infusion treatments for patients with early-stage Alzheimer's disease at their newly opened Sugar Land, TX location.

Key Points: 
  • AdaptIV Infusion in Sugar Land, TX, administering Leqembi® infusions for early-stage Alzheimer's, providing crucial care for patients with this condition.
  • SUGAR LAND, Texas, Dec. 21, 2023 /PRNewswire-PRWeb/ -- AdaptIV Infusion, a state-of-the-art ambulatory infusion clinic specializing in autoimmune disorders, complex chronic conditions, and health and wellness therapies, is now one of a select few facilities administering Leqembi® (lecanemab-irmb) infusion treatments for patients with early-stage Alzheimer's disease at their newly opened Sugar Land, TX location.
  • AdaptIV Infusion's facility in Sugar Land, TX, is conveniently located to serve residents of Sugar Land, Richmond, Rosenberg, Missouri City, Stafford, and the greater Houston area.
  • For more information on AdaptIV Infusion and infusion therapy, visit their website at http://www.adaptivinfusion.com .

ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights

Retrieved on: 
Tuesday, November 14, 2023
Acumen, Neurogranin, Research, Safety, Food, AAIC, Incidence, ALS, Immunoglobulin G, Translational neuroscience, PROMIS, CSF, Patient, MSA, Pharmacokinetics, ITN, Immunization, Therapy, Blood, Neuroscience, ARIA, PMN, Biomarker, Cerebrospinal fluid, Multiple system atrophy, Initiative, Lecanemab, Pharmaceutical industry, Cryptocurrency, Boston

CAMBRIDGE, Massachusetts, Nov. 14, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Key Points: 
  • “The third quarter was marked by significant progress across both our clinical and corporate initiatives,” said Gail Farfel, Ph.D., Chief Executive Officer of ProMIS Neurosciences.
  • These results replicated biomarker findings from the CLARITY-AD trial of lecanemab, which also predominantly targets soluble amyloid beta oligomers.
  • In July 2023, the Company presented preclinical data from mouse vaccination studies at AAIC 2023.
  • Net loss was $2.4 million for the quarter ended September 30, 2023, compared to a net loss of $6.0 million for the same period in 2022.

LEQEMBI® to be launched in Japan for Alzheimer's disease on December 20

Retrieved on: 
Wednesday, December 13, 2023
Ministry of Health (Kuwait), Ministry, Brain, Risk management, Amyloid-related imaging abnormalities, Disease, Risk, History, Patient, CET, Intraparenchymal hemorrhage, Eisai, MCI, Alzheimer's disease, Marketing, Horseshoe kidney, Co-promotion, Ageing, ARIA, Hypersensitivity, NHI, HIV disease progression rates, Lecanemab, Medical device, Pharmaceutical industry, Residential care, Biogen, Health

LEQEMBI obtained manufacturing and marketing approval for the indication of slowing progression of mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD) in Japan on September 25, 2023.

Key Points: 
  • LEQEMBI obtained manufacturing and marketing approval for the indication of slowing progression of mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD) in Japan on September 25, 2023.
  • The launch, planned for December 20, will make Japan the second country to have the product on the market, following the U.S.
    "This is a great Christmas present!
  • Alzheimer's disease patients in Japan will now have access to the first disease modifying treatment.
  • This gives hope for the large aging population in Japan with a great need for new treatment options," says Gunilla Osswald, CEO of BioArctic.

LEQEMBI® to be launched in Japan for Alzheimer's disease on December 20

Retrieved on: 
Wednesday, December 13, 2023
Ministry of Health (Kuwait), Ministry, Brain, Risk management, Amyloid-related imaging abnormalities, Disease, Risk, History, Patient, CET, Intraparenchymal hemorrhage, Eisai, MCI, Alzheimer's disease, Marketing, Horseshoe kidney, Co-promotion, Ageing, ARIA, Hypersensitivity, NHI, HIV disease progression rates, Lecanemab, Medical device, Pharmaceutical industry, Residential care, Biogen, Health

LEQEMBI obtained manufacturing and marketing approval for the indication of slowing progression of mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD) in Japan on September 25, 2023.

Key Points: 
  • LEQEMBI obtained manufacturing and marketing approval for the indication of slowing progression of mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD) in Japan on September 25, 2023.
  • The launch, planned for December 20, will make Japan the second country to have the product on the market, following the U.S.
    "This is a great Christmas present!
  • Alzheimer's disease patients in Japan will now have access to the first disease modifying treatment.
  • This gives hope for the large aging population in Japan with a great need for new treatment options," says Gunilla Osswald, CEO of BioArctic.

Together Senior Health Partners with Leading ACO Rainier Health Network, an Affiliate of CommonSpirit, to Bring Dementia-Specific Care Programs to Dementia Patients

Retrieved on: 
Wednesday, November 15, 2023
Alzheimer's disease, Research, SAN, RADAR, Risk, Chairperson, Dementia, Disease, UCSF, CommonSpirit Health, Patient, Acos, ACO, Moving, NIH, MD, Caregiver, Alzheimer's Association, University, Partnership, Medicare, NPS, Quality of life, Bangladesh Technical Education Board, Accountable care organization, Nursing, Health insurance, Residential care, Together, Lecanemab, Health

SAN FRANCISCO, Nov. 15, 2023 /PRNewswire/ -- Together Senior Health, a brain health company delivering evidence-based solutions for individuals with Alzheimer's Disease and Related Dementias (ADRD), today announced a new strategic partnership with Rainier Health Network, a prominent Accountable Care Organization (ACO) overseeing the healthcare of over 60,000 Medicare patients. Rainier Health Network is solely owned by Virginia Mason Franciscan Health, a division of the national nonprofit health system CommonSpirit Health. The partnership will introduce Together's evidence-based suite of dementia-specific programs, including in-home virtual interventions, to patients across Rainier Health Network in Washington state.

Key Points: 
  • Rainier Health Network is solely owned by Virginia Mason Franciscan Health, a division of the national nonprofit health system CommonSpirit Health.
  • The partnership will introduce Together's evidence-based suite of dementia-specific programs, including in-home virtual interventions, to patients across Rainier Health Network in Washington state.
  • Rainier Health Network, Virginia Mason Franciscan Health and CommonSpirit are deeply committed to serving vulnerable populations, including making dementia care more accessible.
  • "Supporting our members with ADRD is critical," said Dr. Francis Mercado, MD, Chief Medical Officer and Board Chair, Rainier Health Network.

LEQEMBI (lecanemab-Irmb) Named One of Time's Best Inventions of 2023

Retrieved on: 
Wednesday, October 25, 2023
Lecanemab, Alzheimer's disease, BEST, AD, Biogen, Health care, TIME, Pathology, Co-promotion, HIV disease progression rates, Dementia, Eisai, Disease, AI, Patient, Pharmaceutical industry

TOKYO, Oct 25, 2023 - (JCN Newswire) - Eisai Co. Ltd. announced today that TIME has selected Alzheimer's disease (AD) treatment LEQEMBI (lecanemab-irmb) as one of THE BEST INVENTIONS of 2023 in the Medical Care category.

Key Points: 
  • TOKYO, Oct 25, 2023 - (JCN Newswire) - Eisai Co. Ltd. announced today that TIME has selected Alzheimer's disease (AD) treatment LEQEMBI (lecanemab-irmb) as one of THE BEST INVENTIONS of 2023 in the Medical Care category.
  • TIME's annual list of THE BEST INVENTIONS features "200 extraordinary innovations changing lives."
  • TIME then evaluated each contender on a number of key factors, including originality, efficacy, ambition, and impact.
  • We will deliver LEQEMBI to the people with early AD who need it and their families, and aim to continue creating impact on global issues surrounding dementia.